AU Patent

AU2012201453C1 — Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Assigned to Novartis AG · Expires 2024-05-23 · 2y expired

What this patent protects

C;NRPonblDCC\RXSU624275_l.DOC-4uSa/2(ilI ABSTRACT Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3 (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared 5 by various processes.

USPTO Abstract

C;NRPonblDCC\RXSU624275_l.DOC-4uSa/2(ilI ABSTRACT Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3 (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared 5 by various processes.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012201453C1
Jurisdiction
AU
Classification
—
Expires
2024-05-23
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.